Pharvaris N.V. (PHVS)Healthcare | Biotechnology | Zug, Switzerland | NasdaqGS
35.32 USD
-1.68
(-4.541%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 35.40 +0.08 (0.227%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:06 a.m. EDT
The investment case for Pharvaris is currently bifurcated between a fundamentally resilient business and a market pricing in severe distress. Fundamentally, the company shows no signs of a multi-year structural decline; the four-year trajectory is positive (+32%), with the most recent year seeing double-digit growth. The balance sheet is fortress-like, boasting a current ratio of nearly 12 and minimal debt relative to equity, which supports a neutral-to-positive long-term hold despite the lack of profitability. However, the short-term outlook is clouded by aggressive selling from insiders, including the CEO and CMO, and a recent underwriting offering that diluted shareholders. More critically, the options market is screaming caution; the sheer volume of put open interest at deep strikes indicates that speculators are betting on a sharp correction, likely driven by the upcoming earnings report. While the statistical forecast model offers a weak lean upward, it is statistically unreliable and contradicted by the heavy put positioning. Consequently, while the underlying business quality warrants a neutral long-term stance, the immediate risk of a volatility-driven sell-off makes this a risky entry point. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.126159 |
| MSTL | 0.129810 |
| AutoETS | 0.139965 |
| AutoARIMA | 0.140517 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.689 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.224 |
| Market Cap | 2,479,623,168 |
| Forward P/E | -11.35 |
| Beta | -2.33 |
| Previous Name | Pharvaris B.V. |
| Website | https://pharvaris.com |
As of Aug. 22, 2026, 3:06 a.m. EDT: Speculators are heavily positioning for a downside scenario, evidenced by massive open interest in deep out-of-the-money puts ($17.50 strike) compared to negligible call volume. While there is some call activity at higher strikes ($45-$50), the overwhelming capital deployment is in protective puts, suggesting a fear of a significant drop rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.64444447 |
| Address1 | Grafenauweg 8 |
| All Time High | 42.86 |
| All Time Low | 1.77 |
| Ask | 35.7 |
| Ask Size | 1 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 698,130 |
| Average Daily Volume3 Month | 514,951 |
| Average Volume | 514,951 |
| Average Volume10Days | 698,130 |
| Beta | -2.328 |
| Bid | 26.61 |
| Bid Size | 2 |
| Book Value | 5.0018806 |
| City | Zug |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 35.32 |
| Current Ratio | 11.941 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 37.405 |
| Day Low | 35.26 |
| Debt To Equity | 0.224 |
| Display Name | Pharvaris |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -182,166,128 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.868 |
| Enterprise Value | 2,162,014,464 |
| Eps Current Year | -2.76269 |
| Eps Forward | -3.111923 |
| Eps Trailing Twelve Months | -2.9 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 34.5466 |
| Fifty Day Average Change | 0.77339935 |
| Fifty Day Average Change Percent | 0.022387134 |
| Fifty Two Week Change Percent | 64.44444 |
| Fifty Two Week High | 38.13 |
| Fifty Two Week High Change | -2.8100014 |
| Fifty Two Week High Change Percent | -0.07369529 |
| Fifty Two Week Low | 20.65 |
| Fifty Two Week Low Change | 14.67 |
| Fifty Two Week Low Change Percent | 0.71041167 |
| Fifty Two Week Range | 20.65 - 38.13 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 43,700,901 |
| Forward Eps | -3.111923 |
| Forward P E | -11.3498955 |
| Free Cashflow | -90,361,648 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 148 |
| Fullday Change | -1.68 |
| Fullday Change Percent | -4.54054 |
| Fullday Price | 35.4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06081 |
| Held Percent Institutions | 0.92884004 |
| Implied Shares Outstanding | 70,204,506 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. |
| Long Name | Pharvaris N.V. |
| Market | us_market |
| Market Cap | 2,479,623,168 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_402951024 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -170,921,296 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,598,268,767 |
| Number Of Analyst Opinions | 14 |
| Open | 37.0 |
| Operating Cashflow | -155,188,608 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 31 712036410 |
| Post Market Change | 0.08000183 |
| Post Market Change Percent | 0.22650576 |
| Post Market Price | 35.4 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Pharvaris B.V. |
| Previous Close | 37.0 |
| Price Eps Current Year | -12.78464 |
| Price Hint | 2 |
| Price To Book | 7.061344 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.819 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.38462 |
| Region | US |
| Regular Market Change | -1.68 |
| Regular Market Change Percent | -4.54054 |
| Regular Market Day High | 37.405 |
| Regular Market Day Low | 35.26 |
| Regular Market Day Range | 35.26 - 37.405 |
| Regular Market Open | 37.0 |
| Regular Market Previous Close | 37.0 |
| Regular Market Price | 35.32 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 478,507 |
| Return On Assets | -0.42324 |
| Return On Equity | -0.70462 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 70,204,506 |
| Shares Percent Shares Out | 0.0253 |
| Shares Short | 1,775,021 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,136,733 |
| Short Name | Pharvaris N.V. |
| Short Percent Of Float | 0.0307 |
| Short Ratio | 3.95 |
| Source Interval | 15 |
| Symbol | PHVS |
| Target High Price | 75.29549 |
| Target Low Price | 38.149483 |
| Target Mean Price | 49.19393 |
| Target Median Price | 47.904984 |
| Total Cash | 318,282,464 |
| Total Cash Per Share | 4.534 |
| Total Debt | 673,728 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.20505 |
| Two Hundred Day Average Change | 6.11495 |
| Two Hundred Day Average Change Percent | 0.2093799 |
| Type Disp | Equity |
| Volume | 478,507 |
| Website | https://pharvaris.com |
| Zip | 6,300 |